This study is a prospective, randomized, double blind, placebo-controlled clinical trial.
The study will include a total of 44 subjects with clinically measurable keloid lesions. At
least 50% of subjects (at least 22 out of the 44 subjects) will also have documented
diagnosis of concomitant type 2 atopic/allergic) inflammatory diseases. In Phase I, subjects
will be randomized (3:1) to either receive weekly dupilumab or placebo for 24 weeks. At Week
24, both groups will enter Phase II of the study in which all subjects will receive weekly
doses of dupilumab up to Week 52. The treatment period will conclude at Week 52.